Sanofi
https://www.sanofi.com//
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sanofi
Leo’s New Growth Driver Anzupgo Poised For EU Approval
The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology.
RemeGen Rises, Falls Along With Chinese Antibody Ambitions
Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.
Sanofi Confident In Beyfortus Achieving Blockbuster Status In 2024
Beyfortus was a minimal contributor in Sanofi’s second quarter, which beat consensus and prompted an earnings guidance boost, but the RSV antibody’s sales should surge in Q3 and Q4.
US Fast Track Boosts Sumitomo's Oncology Pivot
Sumitomo’s novel AML candidate has shown early clinical promise and been granted US Fast Track status for a form of AML, which looks set to aid the Japanese firm's strategic shift to oncology following recent CNS setbacks.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Ablynx N.V.
- Acambis PLC
- Avigen Inc.
- Bioverativ Inc. (True North Therapeutics, Inc.)
- BiPar Sciences Inc.
- BMP Sunstone Corporation
- Canderm Pharma Inc.
- Celmed BioSciences, Inc.
- Chattem, Inc.
- Connaught Laboratories Ltd.
- Fisons Ltd.
- Fovea Pharmaceuticals, SA
- Genfar S.A.
- Genzyme Corporation
- Groupe Sanofi
- Hoechst Marion Roussel
- Kadmon Holdings, Inc.
- Kiadis Pharma B.V.
- Kiadis Pharma N.V.
- Pluromed
- Principia Biopharma Inc. Protein Sciences Corporation
- Rhone-Poulenc Rorer
- Sanofi-Aventis
- Sanofi-aventis Groupe
- Sanofi Pasteur MSD
- Shantha
- Synthorx, Inc. (THOR)
- TargeGen, Inc.
- Thunder Acquisition
- Tidal Therapeutics
- Translate Bio
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice